Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Oxford University

AstraZeneca AZ

AZ confirms the UK’s MHRA has started rolling review of its COVID-19 vaccine

Regulatory agency will review data as and when it becomes available

- PMLiVE

Roche and Prothena set to advance Parkinson’s disease candidate into phase 2b

Drug moves into late-stage testing despite failing to hit primary endpoint in previous trial

- PMLiVE

Regeneron launches phase 3 COVID-19 antibody trial in the UK

Drug cocktail will be evaluated in patients hospitalised with COVID-19

- PMLiVE

Biogen pays Denali $1bn upfront for Parkinson’s disease programme

Deal includes portfolio of small molecule LRRK2 inhibitors

- PMLiVE

AbbVie exits Voyager alliance for Alzheimer’s/Parkinson’s gene therapies

Biotech company did not disclose the reason for the partnership's end

AstraZeneca AZ

AZ/Oxford’s COVID-19 vaccine proves promising in early trials

Vaccine candidate produced robust immune response

- PMLiVE

Lundbeck drops Parkinson’s drug acquired in €905m deal

Disappointment after drug failed in a mid-stage clinical trial

- PMLiVE

UK, China prep trials of coronavirus vaccine candidates

UK vaccine clinical trials set to begin next month

- PMLiVE

Biogen bulks up in Alzheimer’s again with $2.7bn Sangamo deal

Gains rights to tau-targeting drug ST-501 as part of broader alliance

- PMLiVE

Servier and Oncodesign reach first milestone in Parkinson’s partnership

Oncodesign receives first success payment of €1m

- PMLiVE

Merck acquires pre-clinical biotech Calporta for up to $576m

Expands into early-stage neurodegeneration research field

- PMLiVE

Acadia’s drive to extend use of Nuplazid hits a wall

Shares in company down

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links